Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin‐Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin Treatment
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Drug‐resistant Gram‐positive bacteria, especially Staphylococcus aureus, are emerging as the predominant organisms involved in both nosocomial and community‐acquired infections. Since the 1980s, vancomycin has been the first‐line antibiotic used to treat methicillin‐resistant S aureus. However, allergy and intolerance to vancomycin, the increasing number of vancomycin clinical failures and the existence of vancomycin intermediate‐susceptible isolates of S aureus suggest that new antibiotics are needed. This paper reports the only known case of a successful clinical outcome with long term oral linezolid and rifampin therapy in the management of recurrent and persistent methicillin‐resistant S aureus bacteremia with metastatic infections despite prolonged vancomycin use. More than two years since the initiation of linezolid and rifampin, the study patient has been clinically well with no evidence of adverse drug reactions including cytopenia and hepatic toxicities. Physicians must be aware of the novel developments in antibiotic therapy to treat drug‐resistant bacterial infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Linezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
Sieradzki, K., Roberts, R. B., Haber, S. W., & Tomasz, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400704 · Cited by 638
Staphylococcus aureus resistant to vancomycin--United States, 2002.
(2002) · PubMed · Cited by 569
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K., & Quinn, J. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04376-2 · Cited by 542
STAPHYLOCOCCUS AUREUS RESISTANT TO VANCOMYCIN???UNITED STATES, 2002
&NA; (2002) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200203000-00016 · Cited by 395
Linezolid: A Review of its Use in the Management of Serious Gram-Positive Infections
Perry, C. M., & Jarvis, B. (2001) · Drugs · doi:10.2165/00003495-200161040-00008 · Cited by 275
Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan, 1996
(1997) · American Journal of Infection Control · doi:10.1016/s0196-6553(97)90087-0 · Cited by 224
Staphylococcus aureus with Reduced Susceptibility to Vancomycin
Cosgrove, S. E., Carroll, K. C., & Perl, T. M. (2004) · Clinical Infectious Diseases · doi:10.1086/422458 · Cited by 223
Staphylococcus aureus With Reduced Susceptibility to Vancomycin—United States, 1997
(1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550110029014 · Cited by 223
Pharmacokinetics and Tissue Penetration of Linezolid following Multiple Oral Doses
Gee, T., Ellis, R., Marshall, G., Andrews, J., Ashby, J., & Wise, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1843-1846.2001 · Cited by 220
The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
Hiramatsu, K. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00149-1 · Cited by 191
Rotun, S. S., McMath, V., Schoonmaker, D. J., Maupin, P. S., Tenover, F. C., Hill, B. C., & Ackman, D. M. (1999) · Emerging Infectious Diseases · doi:10.3201/eid0501.990118 · Cited by 167
Rybak, M. J., Cappelletty, D. M., Moldovan, T., Aeschlimann, J. R., & Kaatz, G. W. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.721 · Cited by 147
McClelland, R. S., Fowler, V. G., Sanders, L. L., Gottlieb, G., Kong, L. K., Sexton, D. J., Schmader, K., Lanclos, K. D., & Corey, G. R. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.11.1244 · Cited by 133
Henwood, C. J., Livermore, D. M., Johnson, A. P., James, D., Warner, M., & Gardiner, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.6.931 · Cited by 131
Bacteremia Due to Methicillin-Resistant Staphylococcus aureus
Myers, J. P., & Linnemann, C. C. (1982) · The Journal of Infectious Diseases · doi:10.1093/infdis/145.4.532 · Cited by 120
Kaatz, G. W., & Seo, S. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.799 · Cited by 114
Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999.
Khurshid, M., Chou, T. D., Carey, R. A., Larsen, R. A., Conover, C. S., & Bornstein, S. (2000) · MMWR Morbidity and Mortality Weekly Report · Cited by 109
Linezolid for the Treatment of Resistant Gram-Positive Cocci
Bain, K. T., & Wittbrodt, E. T. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.10276 · Cited by 66
The oxazolidinones as a new family of antimicrobial agent
Marchese, A. E., & Schito, G. C. (2001) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2001.00060.x · Cited by 55
Kibbler, C. C. (2000) · UCL Discovery (University College London) · Cited by 55
Aeschlimann, J. R., Hershberger, E., & Rybak, M. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.1914 · Cited by 53
Efficacy of linezolid in a staphylococcal endocarditis rabbit model
Oramas-Shirey, M. P., Buchanan, L. V., Dileto-Fang, C. L., Dailey, C. F., Ford, C. W., Batts, D. H., & Gibson, J. K. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.3.349 · Cited by 50
Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.
(2000) · PubMed · Cited by 50
Comparative Pharmacokinetics of Teicoplanin and Vancomycin
Harding, I., & Sörgel, F. (2000) · Journal of Chemotherapy · doi:10.1080/1120009x.2000.11782313 · Cited by 49
Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996.
(1997) · PubMed · Cited by 46
Barrett, J. F. (2000) · PubMed · Cited by 43
Evolution of Antibiotic Resistance in Gram-Positive Pathogens
Marchese, A., Schito, G. C., & Debbia, E. A. (2000) · Journal of Chemotherapy · doi:10.1179/joc.2000.12.6.459 · Cited by 40
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Betriú, C., Redondo, M., Boloix, A., Gómez, M., Culebras, E., & Picazo, J. J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.6.911 · Cited by 37
Vancomycin therapy of severe staphylococcal infections
Kirby, W. M. M. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.suppl_d.73 · Cited by 35
Vancomycin concentration in human tissues —preliminary report
Torres-R, J. R., Sanders, C. V., & Lewis, A. C. (1979) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/5.4.475 · Cited by 32
Staphylococcus aureus Bacteremia and Endocarditis: The Role of Diagnostic Evaluation Erratum
Chang, F. ‐. (2012) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e318282a722 · Cited by 30
Vancomycin Therapy in Severe Staphylococcal Infections
Kirby, W. M. M. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.supplement.s236 · Cited by 26
Vancomycin intermediate-resistant Staphylococcus aureus
Turco, T. F. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.18017 · Cited by 25
Yoshida, T., & Hiramatsu, K. (1993) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1993.tb01716.x · Cited by 22
Clinical experience with linezolid in the treatment of resistant gram-positive infections.
Antony, S. J., Diaz-Vasquez, E., & Stratton, C. W. (2001) · PubMed · Cited by 16
Bird's-eye view of nosocomial infections in medical ICU: Blue bugs, fungi, and device-days
Bonten, M. J. M., & Weinstein, R. A. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00001 · Cited by 16
Methicillin-resistant Staphylococcus aureus septic arthritis: Urgent and emergent
Byrne, P. A. C., Hosein, I. K., & Camilleri, J. P. (1998) · Clinical Rheumatology · doi:10.1007/bf01450904 · Cited by 13
Noskin, G. A. (2001) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v30n3p320 · Cited by 12
European survey of glycopeptide susceptibility in Staphylococcus spp.
Schito, G. C., Auckenthaler, R., Marchese, A. E., & Bauernfeind, A. (1999) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.1999.tb00433.x · Cited by 9
Shimada, K., Kobayashi, H., Sunakawa, K., Inamatsu, T., & Yamaguchi, K. (1995) · 日本化学療法学会雑誌 · Cited by 7
Research works printed but not linked: 3
- [3]3. Chang FY. Staphylococcus aureus bacteremia and endocarditis. J Microbiol Immunol Infect 2000;33:63-8.
- [12]12. Niitsuma K, Saito M. Vancomycin inhalation therapy - A pharmacokinetic and clinical study of vancomycin. Antibiot Chemother 1996;122:123-35.
- [35]35. Kaatz GW, Seo SM. In vitro activities of oxazolidinone compound U-100592 and U-100766 against S aureus and S epidermidis. Antimicrob Agents Chemother 1996;40:799-801.
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Rifampin Combination Therapy for Nonmycobacterial Infections
Forrest, G. N., & Tamura, K. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00034-09 · Cited by 242
“Lastly, there was a successful treatment of persistent MRSA bacteremia with metastatic foci by using rifampin-linezolid combination therapy (223).”
BackgroundPurrello, S., Garau, J., Giamarellos‐Bourboulis, E. J., Mazzei, T., Pea, F., Soriano, À., & Stefani, S. (2016) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2016.07.010 · Cited by 128
“Linezolid has been compared with vancomycin for SAB in several case series and observational cohorts [95–99].”
BackgroundGandelman, K., Zhu, T., Fahmi, O. A., Glue, P., Lian, K., Obach, R. S., & Damle, B. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010366445 · Cited by 108
Metadata
- Authors
- Schwalm, J.-D., El-Helou, P., & Lee, C. H.
- Affiliations
- McMaster University (CA)
- Corresponding author
- Lee, Christine H
- Venue
- Canadian Journal of Infectious Diseases and Medical Microbiology
- Publisher
- Wiley
- Published
- 2004-01
- Volume
- 15
- Issue
- 2
- Pages
- 97-100
- ISSN
- 1180-2332 (ISSN-L)
- 1712-9532
- 1918-1493
- PMC
- PMC2094963
- OpenAlex
- W2317216373
- Semantic Scholar
- 6ee4ae48afa489ebec0682c0580e50478dd39d00
- Cited by
- 16
- References
- 45
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 2 · 2021: 1 · 2020: 1 · 2018: 1 · 2016: 1 · 2015: 2 · 2013: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Canadian Journal of Infectious Diseases and Medical Microbiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- methicillin-resistant Staphylococcus aureus, MRSA bacteremia, recurrent bacteremia, linezolid, rifampicin, oral antibiotic therapy, vancomycin resistance, vancomycin intermediate resistance, metastatic infection, adverse drug reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.